Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action: mu-opioid receptor (MOR) agonism and norepinephrine reuptake inhibition (NRI). It is indicated for the management of moderate to severe acute and chronic pain. In the Indian context, it is widely used for post-operative pain, neuropathic pain (e.g., diabetic peripheral neuropathy), and chronic musculoskeletal pain, offering a potentially favorable side-effect profile (less nausea/vomiting, constipation) compared to classical opioids.
Adult: For acute pain: 50-100 mg every 4-6 hours as needed for pain relief. Maximum first-day dose: 700 mg. Subsequent days: Maximum 600 mg/day. For chronic pain/DPN: Start at 50 mg twice daily. Titrate based on pain relief and tolerability in increments of 50 mg twice daily every 3 days. Usual maintenance: 100-250 mg twice daily. Max: 500 mg/day.
Note: Oral administration. Can be taken with or without food. Tablet should be swallowed whole with a glass of water. Do not crush, chew, or split the tablet. For the 100mg strength, dosing interval is typically every 4-6 hours for immediate-release formulations.
Tapentadol exerts its analgesic effect through a unique dual mechanism: 1) Agonist activity at the mu-opioid receptor (MOR), and 2) Inhibition of neuronal norepinephrine reuptake (NRI). The MOR agonism provides central pain relief, while the NRI component enhances descending inhibitory pain pathways in the spinal cord.
Pregnancy: Category C. Use only if potential benefit justifies potential risk to the fetus. Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome (NOWS), which may be life-threatening.
Driving: May impair mental and/or physical abilities required for performing potentially hazardous tasks like driving or operating machinery. Patients should be cautioned accordingly.
| Other Opioids, Benzodiazepines (e.g., Alprazolam), Sedatives/Hypnotics | Additive CNS depression, profound sedation, respiratory depression, coma, death. | Major |
| Monoamine Oxidase Inhibitors (MAOIs) e.g., Phenelzine, Selegiline | Risk of serotonin syndrome, hyperthermia, rigidity, autonomic instability. | Contraindicated |
| Serotonergic Drugs (SSRIs e.g., Sertraline, SNRIs e.g., Venlafaxine, TCAs, Triptans) | Increased risk of serotonin syndrome. | Major |
| CNS Depressants (Alcohol, Antipsychotics, Muscle Relaxants) | Enhanced sedative and CNS depressant effects. | Major |
| Mixed Agonist/Antagonist Opioids (e.g., Pentazocine, Butorphanol) | May reduce analgesic effect and/or precipitate withdrawal symptoms. | Moderate |